Share This Page
Drug Price Trends for NDC 00480-7062
✉ Email this page to a colleague
Average Pharmacy Cost for 00480-7062
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| PERAMPANEL 2 MG TABLET | 00480-7062-56 | 15.48120 | EACH | 2025-11-19 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 00480-7062
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 00480-7062
Introduction
The drug identified by NDC 00480-7062 corresponds to Vasopressin Injection, USP. As a synthetic analog of the naturally occurring hormone vasopressin, it’s primarily used in critical care settings for conditions such as vasodilatory shock, cardiac arrest, and severe hypotension. With a significant role in life-threatening conditions, understanding its market dynamics and future pricing trajectory is crucial for manufacturers, healthcare providers, and policymakers. This analysis covers current market positioning, competitive landscape, regulatory influences, and projected pricing trends over the next five years.
Market Overview
Current Market Landscape
Vasopressin Injection remains a vital drug in intensive care units (ICUs) and emergency settings. Despite the advent of targeted adrenergic agents, vasopressin retains its niche due to specific mechanisms, such as vasoconstriction mediated via V1 receptors, making it irreplaceable in certain clinical protocols.
According to IQVIA data, the overall U.S. market for vasopressin analogs was valued at approximately $250 million in 2022, with a steady growth rate of around 3-4% annually. The utilization rate is closely tied to ICU admissions, cardiac-related emergencies, and hospital protocols.
Manufacturers and Competitive Environment
The primary supplier in the U.S. market includes Fresenius Kabi, which offers Vasostrict (vasopressin injection). Other competitors include compounding pharmacies, which custom-mix vasopressin formulations, although their regulatory status varies. The entry of biosimilars remains limited for vasopressin, largely due to its molecular complexity and the challenges associated with biosimilar development.
Regulatory Status
Vasopressin Injection is FDA-approved, with prescriptions predominantly governed by hospital and ICU protocols. The Drug Price Competition and Patent Term Restoration Act (Hatch-Waxman Act) has provided pathways for generic versions, but none have yet gained significant market penetration as of 2023.
Price Dynamics and Factors Influencing Price Trends
Historical Pricing Trends
The average wholesale price (AWP) for vasopressin injection has traditionally ranged between $15 to $20 per 20-unit vial. Over the past decade, prices have remained relatively stable, with minor fluctuations driven by manufacturing costs and supply chain factors.
Key Price Influencers
- Regulatory and Patent Landscape: The lack of patent exclusivity for vasopressin limits pricing power for manufacturers, resulting in relatively modest price increases.
- Manufacturing Costs: Complex synthesis and stability requirements influence production costs, potentially capping downward price pressures.
- Market Demand: The universality of ICU use ensures consistent demand, but the drug's niche status limits significant volume growth.
- Competitive Entry: The absence of generic or biosimilar competition constrains downward price trends; however, potential biosimilar approvals could impact pricing.
- Healthcare Policy and Reimbursement: Hospital purchasing practices, Medicare, and Medicaid reimbursement policies influence net prices. Policy moves favoring cost containment could exert downward pressure.
Emerging Price Trends (2023–2028)
Predictions suggest modest price increases of approximately 1-2% annually due to inflation, manufacturing costs, and healthcare policy dynamics. Given current market stability and regulatory constraints, dramatic shifts in pricing are unlikely unless disrupted by biosimilar entrants or reforms.
Impact of Biosimilars
While biosimilar development for vasopressin has been slow, FDA's recent accelerations in approving biosimilar pathways could eventually introduce competition. A biosimilar launch could lead to a 15-25% price reduction in wholesale prices within the first two years post-approval, similar to trends observed with other biologic drugs.
Future Market Projections
Demand and Supply Outlook
Demand is expected to grow modestly in line with ICU admissions, which have experienced fluctuations due to shifts in COVID-19 hospitalizations and emerging critical care protocols. The increasing prevalence of conditions requiring vasopressor support, driven by aging populations and chronic disease burdens, supports a steady demand outlook.
Pricing Forecast (2023-2028)
- Short-term (2023–2024): Stable prices with marginal increases (~1-1.5%) aligned with inflation.
- Mid-term (2025–2026): Possible stabilization or slight decrease due to pricing pressures if biosimilars enter the market.
- Long-term (2027–2028): A potential 10-15% reduction if biosimilar competition gains traction or if healthcare reforms incentivize cost-effective alternatives.
Revenue projections for leading manufacturers could stabilize around $250-$300 million annually in the U.S., reflecting demand, pricing, and competitive dynamics.
Policy and Global Trends
International markets mirror U.S. trends but may differ owing to regulatory pathways and healthcare system structures. The World Health Organization (WHO) inclusion of vasopressin in essential medicines lists sustains global demand, especially in resource-constrained settings, potentially influencing price negotiations and generic availability on international markets.
Conclusion
Vasopressin Injection (NDC 00480-7062) remains a critical, stable, and moderately priced component of the critical care pharmacopeia. Its market sustains due to clinical necessity, limited biosimilar competition, and steady demand. Price projections point toward gradual increases driven primarily by inflation and regulation; however, eventual biosimilar entry could reshape its pricing landscape. Stakeholders should monitor biosimilar development, healthcare policy reforms, and ICU utilization trends to adapt their market strategies accordingly.
Key Takeaways
- Market stability is expected with slight annual price increases, barring disruptive biosimilar entries.
- Biosimilar development presents the most significant potential for future price reductions.
- Regulatory and healthcare policies will shape demand and reimbursement models, influencing market dynamics.
- Global demand, especially in resource-limited contexts, may bolster overall sales, despite plateauing in developed markets.
- Stakeholders should prepare for potential price adjustments and strategic shifts should biosimilar approvals materialize.
FAQs
1. What are the primary therapeutic uses of vasopressin injection (NDC 00480-7062)?
Vasopressin injection is mainly used for vasodilatory shock, cardiac arrest, and severe hypotension in critical care settings, leveraging its vasoconstrictive effects to stabilize blood pressure.
2. How might biosimilar competition affect the market for vasopressin?
The entry of biosimilars could lead to price reductions of 15-25% within two years of approval, increasing market competition and potentially reducing healthcare costs.
3. Are there any upcoming regulatory changes likely to impact the vasopressin market?
While no specific regulatory changes are imminent, evolving FDA biosimilar pathways and healthcare reimbursement policies may influence market accessibility and pricing.
4. What factors support the stability of vasopressin’s price over the next five years?
Limited biosimilar presence, consistent ICU demand, and manufacturing complexities contribute to relatively stable prices, with modest inflation-driven increases.
5. Is international demand for vasopressin increasing?
Yes, especially in developing countries where vasopressin is included in WHO’s essential medicines list, preserving global demand even if regional pricing varies.
Sources
[1] IQVIA, U.S. prescription data (2022).
[2] FDA, Vasopressin approvals and biosimilar pathway details.
[3] Industry market reports on critical care drugs (2023).
[4] WHO, Essential medicines list.
More… ↓
